Immix Biopharma Inc.
IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy ( CAR-T ) in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 ( NXC-201 ), currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$46M
▼ -36.2% YoY
Op. Margin
–
ROIC
-21.22%
▲ +73.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$45M
▼ -56.4% YoY
Op. Cash Flow (TTM)
-$45M
▼ -64.0% YoY
Net Debt
-$335M
Net Cash Position
Cash & Equiv.
$336M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with IMMX
Held by ETFs
IMMX is in 11 US ETFs. The largest of them, with IMMX's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.16%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.07%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.04%of the fund
iShares Micro-Cap ETFIWC0.12%of the fund
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC0.06%of the fund
Immix Biopharma (IMMX) in two numbers
Questions about Immix Biopharma
Does Immix Biopharma (IMMX) pay a dividend?
No. Immix Biopharma (IMMX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 30 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IMMX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMMX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.